ATE552271T1 - Antitumorarzneimittel, medikament, zusammensetzung und anwendung davon - Google Patents

Antitumorarzneimittel, medikament, zusammensetzung und anwendung davon

Info

Publication number
ATE552271T1
ATE552271T1 AT08736144T AT08736144T ATE552271T1 AT E552271 T1 ATE552271 T1 AT E552271T1 AT 08736144 T AT08736144 T AT 08736144T AT 08736144 T AT08736144 T AT 08736144T AT E552271 T1 ATE552271 T1 AT E552271T1
Authority
AT
Austria
Prior art keywords
seq
drug
composition
antitumor medicine
acid sequence
Prior art date
Application number
AT08736144T
Other languages
English (en)
Inventor
Sylvie Colin
Mahmood Salman Al
Original Assignee
Gene Signal Int Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP07290440A external-priority patent/EP1980571B1/de
Priority claimed from US11/783,654 external-priority patent/US7674770B2/en
Application filed by Gene Signal Int Sa filed Critical Gene Signal Int Sa
Application granted granted Critical
Publication of ATE552271T1 publication Critical patent/ATE552271T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT08736144T 2007-04-11 2008-04-11 Antitumorarzneimittel, medikament, zusammensetzung und anwendung davon ATE552271T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP07290440A EP1980571B1 (de) 2007-04-11 2007-04-11 Antitumorheilmittel, Medikament, Zusammensetzung und Verwendung davon
US11/783,654 US7674770B2 (en) 2007-04-11 2007-04-11 Anti-tumor drug, medicament, composition, and use thereof
PCT/EP2008/054435 WO2008125635A1 (en) 2007-04-11 2008-04-11 Anti-tumor drug, medicament, composition, and use thereof

Publications (1)

Publication Number Publication Date
ATE552271T1 true ATE552271T1 (de) 2012-04-15

Family

ID=39619422

Family Applications (1)

Application Number Title Priority Date Filing Date
AT08736144T ATE552271T1 (de) 2007-04-11 2008-04-11 Antitumorarzneimittel, medikament, zusammensetzung und anwendung davon

Country Status (8)

Country Link
EP (1) EP2144927B1 (de)
JP (2) JP5539184B2 (de)
CN (1) CN101679499B (de)
AT (1) ATE552271T1 (de)
AU (1) AU2008237952B2 (de)
CA (1) CA2683463A1 (de)
ES (1) ES2385115T3 (de)
WO (1) WO2008125635A1 (de)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101679499B (zh) * 2007-04-11 2015-03-11 基因信号国际公司 抗肿瘤药物、药剂、组合物及其用途
CN113912705B (zh) * 2015-07-27 2023-12-22 上海贺普药业股份有限公司 一种肿瘤抑制肽
CN108181214B (zh) * 2018-02-09 2020-06-30 北京爱泰浦生物医药科技有限责任公司 使用atap肽治疗疾病的方法和组合物
CN108014325B (zh) * 2018-02-09 2023-12-05 北京爱泰浦生物医药科技有限责任公司 多肽在治疗癌症中的应用
CN113583095B (zh) * 2021-07-29 2023-07-28 上海卡序生物医药科技有限公司 抗肿瘤多肽及其用途

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998031799A2 (en) * 1997-01-21 1998-07-23 Human Genome Sciences, Inc. Polynucleotides and polypeptides encoding receptors
GB0016362D0 (en) * 2000-07-03 2000-08-23 Chiron Spa Tetraspanin modulation
BR0113674A (pt) * 2000-09-01 2003-06-03 Bioacta Ltd Peptìdeos antiangiogênicos
FR2836687A1 (fr) * 2002-03-04 2003-09-05 Gene Signal Genes impliques dans la regulation de l'angiogenese, preparations pharmaceutiques les contenant et leurs applications
CA2501131A1 (en) * 2002-10-04 2004-04-22 Van Andel Research Institute Molecular sub-classification of kidney tumors and the discovery of new diagnostic markers
JP2007523099A (ja) * 2004-02-20 2007-08-16 ノボ　ノルディスク　アクティーゼルスカブ 組み合わせ療法
CN101679499B (zh) * 2007-04-11 2015-03-11 基因信号国际公司 抗肿瘤药物、药剂、组合物及其用途

Also Published As

Publication number Publication date
CA2683463A1 (en) 2008-10-23
EP2144927A1 (de) 2010-01-20
EP2144927B1 (de) 2012-04-04
CN101679499B (zh) 2015-03-11
AU2008237952B2 (en) 2013-02-07
ES2385115T3 (es) 2012-07-18
JP2014114292A (ja) 2014-06-26
CN101679499A (zh) 2010-03-24
JP5539184B2 (ja) 2014-07-02
AU2008237952A1 (en) 2008-10-23
JP2010523628A (ja) 2010-07-15
WO2008125635A1 (en) 2008-10-23

Similar Documents

Publication Publication Date Title
ES2563646T3 (es) Composiciones y métodos relacionados con variantes de la proteína A (SpA)
NZ595063A (en) Polypeptides from neisseria meningitidis
NZ598348A (en) Combined use of gdf traps and erythropoietin receptor activators to increase red blood cell levels
RU2008136324A (ru) Желудочно-кишечный пролиферативный фактор и его применения
EA201200515A1 (ru) Полипептиды и их применение
WO2008118017A3 (en) Prame derived peptides and immunogenic compositions comprising these
MX340014B (es) Composicion farmaceutica para el tratamiento y/o prevencion del cancer.
MX2012008998A (es) Composicion farmaceutica para el tratamiento y/o prevencion del cancer.
MX2012009000A (es) Composicion farmaceutica para el tratamiento y/o prevencion del cancer.
MX340016B (es) Composicion farmaceutica para el tratamiento y/o prevencion del cancer.
BR112014007069A2 (pt) proteínas de fusão para o tratamento de distúrbios metabólicos
MX357505B (es) Composicion farmaceutica para el tratamiento y/o prevencion del cancer.
PE20121393A1 (es) Analogo peptidico de oxintomodulina
MX360208B (es) Composicion farmaceutica para el tratamiento y/o prevencion del cancer.
EA201270517A1 (ru) Микобактериальные вакцины
RU2013126581A (ru) Мутанты стрептокиназы и их ковалентно модифицированные формы
BR112012029975A2 (pt) peptídeo como medicamento, em particular para o tratamento do câncer.
MX2008009493A (es) Peptido novedoso y uso del mismo.
MX2019006515A (es) Composiciones que comprenden peptido wkdeagkplvk.
UA100127C2 (ru) Пептид cdh3 и лекарственное средство, содержащее его
BRPI0607097B8 (pt) uso de um peptídeo imunogênico para a fabricação de um medicamento para o tratamento, prevenção ou redução de infecção por papilomavírus
ATE552271T1 (de) Antitumorarzneimittel, medikament, zusammensetzung und anwendung davon
NZ703514A (en) Fviii peptides for immune tolerance induction and immunodiagnostics
WO2011053789A3 (en) Pharmaceutical composition and methods to enhance cytotoxic t-cell recognition and maintain t-cell memory against a pathogenic disease
RU2016135003A (ru) Новые виды лечения